

**Experiment Number:** 93020-04  
**Test Type:** 90-DAY  
**Route:** SKIN APPLICATION  
**Species/Strain:** Mouse/B6C3F1

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH  
AVERAGE SEVERITY GRADES[b]**  
**Test Compound:** Diisopropylcarbodiimide  
**CAS Number:** 693-13-0

**Date Report Requested:** 10/21/2014  
**Time Report Requested:** 18:48:19  
**First Dose M/F:** NA / NA  
**Lab:** MBA

<b>C Number:</b>	C93020
<b>Lock Date:</b>	05/16/1995
<b>Cage Range:</b>	All
<b>Date Range:</b>	All
<b>Reasons For Removal:</b>	All
<b>Removal Date Range:</b>	All
<b>Treatment Groups:</b>	All
<b>Study Gender:</b>	Both
<b>PWG Approval Date</b>	NONE

Experiment Number: 93020-04  
 Test Type: 90-DAY  
 Route: SKIN APPLICATION  
 Species/Strain: Mouse/B6C3F1

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH  
 AVERAGE SEVERITY GRADES[b]**  
 Test Compound: Diisopropylcarbodiimide  
 CAS Number: 693-13-0

Date Report Requested: 10/21/2014  
 Time Report Requested: 18:48:19  
 First Dose M/F: NA / NA  
 Lab: MBA

B6C3F1 Mouse MALE	0	MG/KG	17.5	MG/KG	35	MG/KG	70	MG/KG	140	MG/KG	280	MG/KG
<b>Disposition Summary</b>												
Animals Initially In Study	10		10		10		10		10		10	
Early Deaths												
Moribund Sacrifice									9		10	
Survivors												
Terminal Sacrifice	10		10		10		10		1			
Animals Examined Microscopically	10		10		10		10		10		10	
<b>ALIMENTARY SYSTEM</b>												
Esophagus	(10)		(0)		(0)		(9)		(10)		(10)	
Gallbladder	(10)		(0)		(0)		(9)		(9)		(10)	
Inflammation, Acute							1 [1.0]					
Intestine Large, Cecum	(10)		(0)		(0)		(10)		(10)		(10)	
Intestine Large, Colon	(10)		(0)		(0)		(10)		(10)		(10)	
Intestine Large, Rectum	(10)		(0)		(0)		(10)		(10)		(10)	
Intestine Small, Duodenum	(10)		(0)		(0)		(10)		(10)		(10)	
Intestine Small, Ileum	(10)		(0)		(0)		(10)		(10)		(10)	
Intestine Small, Jejunum	(10)		(0)		(0)		(10)		(10)		(10)	
Liver	(10)		(0)		(0)		(10)		(10)		(10)	
Centrilobular, Vacuolization Cytoplasmic Hepatocyte, Necrosis, Focal							1 [1.0]				2 [1.5]	
Pancreas	(10)		(0)		(0)		(10)		(10)		(10)	
Acinus, Necrosis, Focal											1 [2.0]	
Salivary Glands	(10)		(0)		(0)		(10)		(10)		(10)	
Infiltration Cellular, Lymphocyte, Focal	1 [1.0]											
Stomach, Forestomach	(10)		(0)		(0)		(10)		(10)		(10)	
Stomach, Glandular	(10)		(0)		(0)		(10)		(10)		(10)	
<b>CARDIOVASCULAR SYSTEM</b>												
Blood Vessel	(10)		(0)		(0)		(10)		(10)		(10)	

a - Number of animals examined microscopically at site and number of animals with lesion  
 b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Experiment Number: 93020-04

Test Type: 90-DAY

Route: SKIN APPLICATION

Species/Strain: Mouse/B6C3F1

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]**

Test Compound: Diisopropylcarbodiimide

CAS Number: 693-13-0

Date Report Requested: 10/21/2014

Time Report Requested: 18:48:19

First Dose M/F: NA / NA

Lab: MBA

B6C3F1 Mouse MALE	0	MG/KG	17.5	MG/KG	35	MG/KG	70	MG/KG	140	MG/KG	280	MG/KG
Heart	(10)		(0)		(0)		(10)		(10)		(10)	
<b>ENDOCRINE SYSTEM</b>												
Adrenal Cortex	(10)		(0)		(0)		(10)		(10)		(10)	
Adrenal Medulla	(10)		(0)		(0)		(10)		(10)		(10)	
Islets, Pancreatic	(10)		(0)		(0)		(10)		(10)		(10)	
Parathyroid Gland	(8)		(0)		(0)		(7)		(6)		(7)	
Pituitary Gland	(8)		(0)		(0)		(10)		(9)		(10)	
Thyroid Gland	(10)		(0)		(0)		(10)		(10)		(10)	
<b>GENERAL BODY SYSTEM</b>												
None												
<b>GENITAL SYSTEM</b>												
Epididymis	(10)		(0)		(0)		(10)		(10)		(10)	
Penis	(0)		(0)		(0)		(0)		(1)		(0)	
Preputial Gland	(10)		(0)		(0)		(10)		(9)		(10)	
Bilateral, Cyst	1 [2.0]											
Cyst									1 [2.0]			
Prostate	(10)		(0)		(0)		(10)		(9)		(10)	
Seminal Vesicle	(10)		(0)		(0)		(10)		(10)		(10)	
Atrophy									1 [1.0]			
Testes	(10)		(0)		(0)		(10)		(10)		(10)	
<b>HEMATOPOIETIC SYSTEM</b>												
Bone Marrow	(10)		(0)		(0)		(10)		(10)		(10)	
Angiectasis									3 [1.7]			
Hyperplasia											1 [1.0]	
Lymph Node, Mandibular	(9)		(0)		(0)		(10)		(10)		(10)	
Atrophy									1 [2.0]			
Hyperplasia, Lymphoid	1 [2.0]											

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Experiment Number: 93020-04

Test Type: 90-DAY

Route: SKIN APPLICATION

Species/Strain: Mouse/B6C3F1

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]**

Test Compound: Diisopropylcarbodiimide

CAS Number: 693-13-0

Date Report Requested: 10/21/2014

Time Report Requested: 18:48:19

First Dose M/F: NA / NA

Lab: MBA

B6C3F1 Mouse MALE	0	MG/KG	17.5	MG/KG	35	MG/KG	70	MG/KG	140	MG/KG	280	MG/KG
Lymph Node, Mesenteric	(10)		(0)		(0)		(10)		(10)		(10)	
Atrophy									1 [2.0]		1 [2.0]	
Necrosis	6 [1.2]						8 [1.1]				3 [1.0]	
Spleen	(10)		(9)		(4)		(10)		(10)		(10)	
Lymph Follic, Atrophy									1 [2.0]			
Lymph Follic, Necrosis	9 [1.0]		9 [1.0]		4 [1.0]		8 [1.3]		1 [1.0]		1 [1.0]	
Thymus	(10)		(0)		(0)		(10)		(9)		(10)	
Cyst											1 [2.0]	
Thymocyte, Atrophy									7 [3.1]		7 [2.3]	
Thymocyte, Necrosis							1 [2.0]					
<b>INTEGUMENTARY SYSTEM</b>												
Mammary Gland	(1)		(0)		(0)		(0)		(1)		(0)	
Skin	(10)		(10)		(10)		(10)		(10)		(10)	
Epidermis, SOA, Hyperplasia	2 [1.5]		1 [2.0]		1 [2.0]		9 [1.0]		10 [1.8]		6 [1.8]	
Epidermis, SOA, Necrosis					1 [1.0]						8 [2.6]	
SOA, Inflammation, Acute											2 [3.5]	
SOA, Inflammation, Chronic Active	2 [2.5]		1 [2.0]		1 [2.0]				9 [1.3]		8 [3.5]	
SOA, Necrosis											1 [2.0]	
SOA, Sebaceous Gl, Hyperplasia							2 [1.0]		5 [1.6]			
Skin, Control	(0)		(0)		(0)		(1)		(0)		(1)	
Inflammation, Chronic											1 [1.0]	
Inflammation, Chronic Active							1 [1.0]					
<b>MUSCULOSKELETAL SYSTEM</b>												
Bone	(10)		(0)		(0)		(10)		(10)		(10)	
Skeletal Muscle	(10)		(0)		(0)		(10)		(10)		(10)	
<b>NERVOUS SYSTEM</b>												
Brain	(10)		(0)		(0)		(10)		(10)		(10)	
Peripheral Nerve	(10)		(0)		(0)		(10)		(10)		(10)	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Experiment Number: 93020-04  
 Test Type: 90-DAY  
 Route: SKIN APPLICATION  
 Species/Strain: Mouse/B6C3F1

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH  
 AVERAGE SEVERITY GRADES[b]**  
 Test Compound: Diisopropylcarbodiimide  
 CAS Number: 693-13-0

Date Report Requested: 10/21/2014  
 Time Report Requested: 18:48:19  
 First Dose M/F: NA / NA  
 Lab: MBA

B6C3F1 Mouse MALE	0	MG/KG	17.5	MG/KG	35	MG/KG	70	MG/KG	140	MG/KG	280	MG/KG
Spinal Cord	(10)		(0)		(0)		(10)		(10)		(10)	
RESPIRATORY SYSTEM												
Lung	(10)		(0)		(0)		(10)		(10)		(10)	
Artery, Inflammation, Chronic Active, Focal							1 [2.0]					
Nose	(10)		(0)		(0)		(10)		(10)		(10)	
Olfactory Epi, Degeneration, Hyaline									1 [1.0]		1 [1.0]	
Olfactory Epi, Necrosis											1 [1.0]	
Trachea	(10)		(0)		(0)		(10)		(10)		(10)	
SPECIAL SENSES SYSTEM												
None												
URINARY SYSTEM												
Kidney	(10)		(0)		(0)		(10)		(10)		(10)	
Renal Tubule, Degeneration							1 [1.0]		1 [1.0]			
Urinary Bladder	(10)		(0)		(0)		(10)		(10)		(10)	
Inflammation, Chronic	1 [1.0]											

\*\*\*END OF MALE DATA\*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion  
 b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Experiment Number: 93020-04  
 Test Type: 90-DAY  
 Route: SKIN APPLICATION  
 Species/Strain: Mouse/B6C3F1

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH  
 AVERAGE SEVERITY GRADES[b]**  
 Test Compound: Diisopropylcarbodiimide  
 CAS Number: 693-13-0

Date Report Requested: 10/21/2014  
 Time Report Requested: 18:48:19  
 First Dose M/F: NA / NA  
 Lab: MBA

B6C3F1 Mouse FEMALE	0	MG/KG	17.5	MG/KG	35	MG/KG	70	MG/KG	140	MG/KG	280	MG/KG
<b>Disposition Summary</b>												
Animals Initially In Study	10		10		10		10		10		10	
Early Deaths												
Moribund Sacrifice									8		10	
Natural Death									1			
Survivors												
Accidentally Killed	6		8		4		7		1			
Terminal Sacrifice	4		2		6		3					
Animals Examined Microscopically	10		10		10		10		10		10	
<b>ALIMENTARY SYSTEM</b>												
Esophagus	(10)		(0)		(0)		(10)		(10)		(10)	
Gallbladder	(10)		(0)		(0)		(10)		(10)		(10)	
Intestine Large, Cecum	(10)		(0)		(0)		(10)		(10)		(10)	
Intestine Large, Colon	(10)		(0)		(0)		(10)		(10)		(10)	
Intestine Large, Rectum	(10)		(0)		(0)		(10)		(10)		(10)	
Intestine Small, Duodenum	(10)		(0)		(0)		(10)		(10)		(10)	
Intestine Small, Ileum	(10)		(0)		(0)		(10)		(10)		(10)	
Necrosis									1 [2.0]			
Intestine Small, Jejunum	(10)		(0)		(0)		(8)		(9)		(10)	
Liver	(10)		(0)		(0)		(10)		(10)		(10)	
Hepatocyte, Vacuolization Cytoplasmic									1 [1.0]		1 [1.0]	
Inflammation, Acute	1 [1.0]											
Mineralization, Focal	1 [2.0]											
Pancreas	(10)		(0)		(0)		(10)		(10)		(10)	
Acinus, Atrophy, Focal									1 [1.0]			
Salivary Glands	(10)		(0)		(0)		(10)		(10)		(10)	
Infiltration Cellular, Lymphocyte	1 [1.0]											
Stomach, Forestomach	(10)		(0)		(0)		(10)		(10)		(10)	

a - Number of animals examined microscopically at site and number of animals with lesion  
 b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Experiment Number: 93020-04

Test Type: 90-DAY

Route: SKIN APPLICATION

Species/Strain: Mouse/B6C3F1

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]**

Test Compound: Diisopropylcarbodiimide

CAS Number: 693-13-0

Date Report Requested: 10/21/2014

Time Report Requested: 18:48:19

First Dose M/F: NA / NA

Lab: MBA

<b>B6C3F1 Mouse FEMALE</b>	<b>0</b>	<b>MG/KG</b>	<b>17.5</b>	<b>MG/KG</b>	<b>35</b>	<b>MG/KG</b>	<b>70</b>	<b>MG/KG</b>	<b>140</b>	<b>MG/KG</b>	<b>280</b>	<b>MG/KG</b>
Ulcer, Focal Stomach, Glandular	(10)		(0)		(0)		(10)		(10)		1 [1.0]	(10)
<b>CARDIOVASCULAR SYSTEM</b>												
Blood Vessel	(10)		(0)		(0)		(9)		(10)		(10)	(10)
Heart	(10)		(0)		(0)		(10)		(10)		(10)	(10)
<b>ENDOCRINE SYSTEM</b>												
Adrenal Cortex	(10)		(0)		(0)		(10)		(10)		(10)	(10)
Bilateral, Capsule, Hyperplasia	3 [1.0]						2 [1.0]		1 [1.0]			
Bilateral, Vacuolization Cytoplasmic Capsule, Hyperplasia	3 [1.3]						3 [1.0]		1 [1.0]			
Adrenal Medulla	(10)		(0)		(0)		(10)		(10)		(10)	(10)
Islets, Pancreatic	(10)		(0)		(0)		(10)		(10)		(10)	(10)
Parathyroid Gland	(8)		(0)		(0)		(10)		(7)		(5)	(5)
Pituitary Gland	(9)		(0)		(0)		(7)		(8)		(7)	(7)
Thyroid Gland	(10)		(0)		(0)		(10)		(10)		(10)	(10)
Follicle, Cyst											1 [1.0]	
<b>GENERAL BODY SYSTEM</b>												
None												
<b>GENITAL SYSTEM</b>												
Clitoral Gland	(7)		(0)		(0)		(7)		(4)		(3)	(3)
Atrophy									1 [2.0]			
Cyst									1 [2.0]			
Ovary	(10)		(0)		(0)		(10)		(10)		(10)	(10)
Cyst	1 [2.0]											
Uterus	(10)		(0)		(0)		(10)		(10)		(10)	(10)
<b>HEMATOPOIETIC SYSTEM</b>												
Bone Marrow	(10)		(0)		(0)		(10)		(10)		(10)	(10)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Experiment Number: 93020-04

Test Type: 90-DAY

Route: SKIN APPLICATION

Species/Strain: Mouse/B6C3F1

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH AVERAGE SEVERITY GRADES[b]**

Test Compound: Diisopropylcarbodiimide

CAS Number: 693-13-0

Date Report Requested: 10/21/2014

Time Report Requested: 18:48:19

First Dose M/F: NA / NA

Lab: MBA

<b>B6C3F1 Mouse FEMALE</b>	<b>0</b>	<b>MG/KG</b>	<b>17.5</b>	<b>MG/KG</b>	<b>35</b>	<b>MG/KG</b>	<b>70</b>	<b>MG/KG</b>	<b>140</b>	<b>MG/KG</b>	<b>280</b>	<b>MG/KG</b>
Lymph Node, Mandibular Hemorrhage	(10)		(0)		(0)		(10)		(10)		(8)	
Lymph Node, Mesenteric Hyperplasia, Lymphoid Necrosis	(9) 1 [1.0]		(0)		(0)		(9)		(10)		(9)	
Spleen Hematopoietic Cell Proliferation Hemorrhage	(10)		(0)		(1)		(10)		(10)		(10)	
Lymph Follic, Necrosis	2 [1.0]						2 [1.0]		1 [1.0]		1 [1.0]	
Thymus Thymocyte, Atrophy	(10)		(0)		(0)		(10)		(9)		(10)	
									7 [3.9]		7 [3.9]	
<b>INTEGUMENTARY SYSTEM</b>												
Mammary Gland	(10)		(0)		(0)		(9)		(9)		(10)	
Skin Epidermis, SOA, Hyperplasia	(9)		(10)		(10)		(10)		(10)		(10)	
Epidermis, SOA, Necrosis					2 [1.0]		10 [1.6]		10 [2.0]		10 [1.8]	
SOA, Inflammation, Chronic Active					2 [1.0]		8 [1.3]		9 [1.6]		10 [3.1]	
SOA, Sebaceous Gland, Hyperplasia									3 [1.3]			
Skin, Control Epidermis, Hyperplasia	(1)		(0)		(0)		(2)		(2)		(0)	
Epidermis, Hyperplasia, Focal							1 [1.0]		1 [1.0]			
Inflammation, Chronic	1 [1.0]						1 [1.0]		2 [1.0]			
Inflammation, Chronic Active							1 [1.0]					
<b>MUSCULOSKELETAL SYSTEM</b>												
Bone	(10)		(0)		(0)		(10)		(10)		(10)	
Skeletal Muscle	(10)		(0)		(0)		(10)		(10)		(10)	
<b>NERVOUS SYSTEM</b>												
Brain	(9)		(0)		(0)		(10)		(9)		(10)	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Experiment Number: 93020-04  
 Test Type: 90-DAY  
 Route: SKIN APPLICATION  
 Species/Strain: Mouse/B6C3F1

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH  
 AVERAGE SEVERITY GRADES[b]**  
 Test Compound: Diisopropylcarbodiimide  
 CAS Number: 693-13-0

Date Report Requested: 10/21/2014  
 Time Report Requested: 18:48:19  
 First Dose M/F: NA / NA  
 Lab: MBA

B6C3F1 Mouse FEMALE	0	MG/KG	17.5	MG/KG	35	MG/KG	70	MG/KG	140	MG/KG	280	MG/KG
Brain, Cerebellum	(1)		(0)		(0)		(0)		(0)		(0)	
Inflammation, Chronic	1 [2.0]											
Peripheral Nerve	(9)		(0)		(0)		(10)		(10)		(10)	
Peripheral Nerve, Sciatic	(1)		(0)		(0)		(0)		(0)		(0)	
Degeneration	1 [2.0]											
Spinal Cord	(10)		(0)		(0)		(10)		(10)		(10)	
<b>RESPIRATORY SYSTEM</b>												
Lung	(10)		(0)		(0)		(10)		(10)		(10)	
Congestion											1 [2.0]	
Hemorrhage									2 [1.5]		1 [2.0]	
Infiltration Cellular, Lymphocyte, Focal							1 [1.0]					
Inflammation, Granulomatous							1 [1.0]					
Nose	(10)		(0)		(0)		(10)		(10)		(10)	
Olfactory Epi, Degeneration, Hyaline	2 [2.0]								1 [1.0]		1 [1.0]	
Respirat Epith, Degeneration, Hyaline	8 [1.5]						6 [1.0]		2 [1.5]			
Trachea	(10)		(0)		(0)		(10)		(10)		(10)	
<b>SPECIAL SENSES SYSTEM</b>												
None												
<b>URINARY SYSTEM</b>												
Kidney	(10)		(0)		(0)		(10)		(10)		(10)	
Urinary Bladder	(10)		(0)		(0)		(10)		(10)		(9)	

**\*\* END OF REPORT \*\***

a - Number of animals examined microscopically at site and number of animals with lesion  
 b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)